HC Wainwright & Co. Reiterates Buy on Sutro Biopharma, Maintains $16 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Sutro Biopharma (NASDAQ:STRO) and maintained a $16 price target.
August 11, 2023 | 4:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sutro Biopharma's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $16.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $16 indicates the firm's continued confidence in the company's potential. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100